NCT06653777View on ClinicalTrials.gov

Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Solid Tumor, Miscellaneous
Interventions
DRUG

Pemigatinib

Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).

Trial Locations (6)

54500

ACTIVE_NOT_RECRUITING

Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy

Unknown

RECRUITING

CHU de BREST, Brest

ACTIVE_NOT_RECRUITING

Centre Antoine Lacassagne, Nice

NOT_YET_RECRUITING

Institut Curie, Paris

ACTIVE_NOT_RECRUITING

CHU Poitiers, Poitiers

ACTIVE_NOT_RECRUITING

CHU Saint Etienne, Saint-Priest-en-Jarez

Sponsors

Collaborators (1)

Incyte BioSciences France
All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Incyte BioSciences France

INDUSTRY

lead

UNICANCER

OTHER

NCT06653777 - Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells | Biotech Hunter | Biotech Hunter